The paper behind each source number
Tesamorelin Studies with Their Sources
You can check every paper used here. The list includes main trials, a review combining five trials, a timing study, and a liver-safety report.
Where can you check a tesamorelin claim?
A small source number leads to this list. Open the matching paper for its full finding. Your doctor can use these sources too.
The 3 main trial reports followed people with HIV [1][2][3]. A smaller study followed healthy men [4].
One paper timed how quickly tesamorelin left blood [11]. A 2026 review combined five trials [15]. A federal report examined possible liver harm [5].
The papers ask different questions. Check who took part and how long each study lasted. None proves routine weight loss.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. ↗
- Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. ↗
- Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. ↗
- Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. ↗
- National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf (NIH); 2018. ↗
- Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opin Investig Drugs. 2009;18(3):303-310. ↗
- Makimura H, Murphy CA, Feldpausch MN, Grinspoon SK. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. J Clin Endocrinol Metab. 2014;99(1):338-343. ↗
- Norman C, Miles J, Bowers CY, Veldhuis JD. Differential pulsatile secretagogue control of GH secretion in healthy men. Am J Physiol Regul Integr Comp Physiol. 2013;304(9):R712-R719. ↗
- Veldhuis JD, Keenan DM, et al. Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism. Eur J Endocrinol. 2009;161(2):293-300. ↗
- Veldhuis JD, Erickson D, et al. Endogenous estrogen regulates somatostatin-induced rebound GH secretion in postmenopausal women. J Clin Endocrinol Metab. 2016;101(11):4298-4304. ↗
- Gonzalez-Sales M, Barriere O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. J Pharmacokinet Pharmacodyn. 2015;42(3):287-299. ↗
- Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011;25(10):1281-1288. ↗
- Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dube MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395-1402. ↗
- Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. PLoS One. 2015;10(10):e0140358. ↗
- Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026. Advance online publication. ↗